The companies will jointly offer pathology and molecular testing services to PPD's pharmaceutical and biotechnology customers.
The system is designed to identify intact secondary metabolite gene clusters for natural product discovery in a fungal model organism.
The companies will pair Freenome's AI genomics platform with various Qiagen molecular analysis platforms and co-market the technologies to pharmaceutical companies.
By combining iPSCs, CRISPR gene editing, and transcriptomic approaches, researchers examined the effects of an Alzheimer's disease risk variant on brain cells.
Two new studies used ancient and modern-day genomes to tease apart Indigenous migrations in the Americas and ancestry patterns by the first Icelandic settlers.
The company is developing tests based on the analysis of the spatial patterns of chromosomes by tagging and imaging their telomeres.
Researchers searched exome sequences of more than 100,000 individuals for associations to more than a dozen quantitative human traits and 10 diseases.
Five Prime will use an IHC CDx to analyze the use of investigational drug candidates in patients with advanced gastric or gastroesophageal junction cancer.
The NMI Natural and Medical Sciences Institute at the university and its affiliate will use the patents to expand their cell-based research service offerings.
The French diagnostics firm said it will use the funding to support its merger and acquisition strategy.
The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.
The company entered a securities purchase agreement through which it has raised gross proceeds of $650,000 and paid down a portion of the company's debt.
The merger, which was previously scuttled and later revived with Rosetta shareholder approval, was due to close on May 27.
A University of Michigan-led team found that the lncRNA ARLNC1 forms a feedback loop with the androgen receptor to promote progression in prostate cancer.
The agreement will combine LexaGene's microfluidic instrument and targeted sequencing technology developed at the Stanford University School of Medicine.
Myriad will merge Counsyl’s reproductive tests with its preventive care business unit into a new business unit called Myriad Women’s Health.
The new funding from Business Finland comes on the heels of a successful financing round announced last week.
The genetic risk of schizophrenia is influenced by early-life complications and the placenta differentially expresses these complication-linked genes, a new study says.
Using genotyping profiles for nearly 256,000 individuals, researchers uncovered more than 100 new loci involved in nearsightedness.
Last week, GenomeWeb's readers were most interested in Grail raising $300 million in an oversubscribed Series C financing round.
The firms will use Adaptive's ClonoSeq assay to assess minimal residual disease in multiple myeloma patients treated with Sanofi's isatuximab.
Centogene will help Aldeyra identify patients with Sjögren-Larsson Syndrome, a rare genetic disease for which Aldeyra is developing a treatment.
BioGx now offers 11 CE-marked infectious disease tests that run on Becton Dickinson's BD Max platform.
A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.
A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.
In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.
A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.